More Business Wire
View Older Stories View Newer Stories-
SunRock Biopharma and Chime Biologics Announce Strategic Collaboration to Advance Development of Anti-CCR9 Antibody SRB5
-
USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call
-
CatalYm Presents Long-Term Phase 1/2a Data Confirming Sustained Responses with Visugromab in CPI-Refractory Tumors at ESMO 2025
-
Omdia: AMOLED 2H25 Display Revenues to Reach $29 Billion, Falling Short of 2H24
-
Omdia: Music Publishing Revenue Growth to Outshine Recorded-Music Over the Next Five Years
-
New Needle-Free Treatment Option for Life-Threatening Anaphylaxis, EURneffy®, Now Available in the UK
-
RWS Appoints Industry Trailblazer Michael Wayne as Head of Media and Entertainment
-
Leading Global Businesses Unite to Launch Carbon Measures
-
Imagine Communications Acquires Pixel Power From Rohde & Schwarz
-
StratifAI Joins With MSK iHub Challenge Cohort to Advance Validation of Polaris™ Through Access to World-Class Clinical Datasets
-
Caranx Medical (CarvOlix group) to Showcase Latest Updates at the 37th Annual Transcatheter Cardiovascular Therapeutics® Conference (TCT)
-
Valeo Foods Group Recognised for Sustainability Leadership with EcoVadis Platinum Medal
-
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO
-
Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO
-
Lazard Appoints Edouard Panié as Managing Director and Co-Head of European Financial Sponsors Coverage
-
Abyan Capital Launches Shariah-Compliant, Self-Directed Access to US Markets with Alpaca
-
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
-
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
-
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
-
AM Best to Host Annual MENA Insurance Market Briefing in Dubai
-
Lone Star Announces Sale of Xella to Holcim
-
Bass Pro Shops Ranked Highest in 2025 Boat Industry Study Measuring Response to Sales Customer Calls
-
Worldwide First: Biedermann Motech Further Expands its MOSS!MODULARITY Platform and Announces Introduction of Multiple New Products
-
AM Best to Participate at 2025 Shanghai International Reinsurance Conference
-
AM Best to Host Market Briefing at 2025 Singapore International Reinsurance Conference
-
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
-
The Republic of Korea Selects L3Harris for Airborne Early Warning and Control Aircraft Program
-
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
-
FreightTracker Receives Strategic Growth Investment from Arcadea Group
-
American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
-
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the
-
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
-
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-O
-
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
-
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative brea
-
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
-
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
-
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
-
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
-
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
-
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom
-
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
-
Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study
-
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
-
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
-
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
-
13th Annual Energy Day Festival Sparks STEM Interest Among Houston Students
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
